UK secures Japanese antiviral Favipiravir amid Hantavirus preparedness

UK—The UK has received a shipment of the antiviral medicine favipiravir from the Japanese government as health authorities strengthen preparations against a potential spread of hantavirus within the country.

The medicine, developed by Fujifilm Holdings Corporation subsidiary Toyama Chemical, was delivered to the UK last weekend following discussions between the two governments.

Although officials did not reveal the number of doses supplied or disclose any financial arrangements linked to the delivery, the move highlights growing international cooperation in infectious disease preparedness.

The antiviral drug was originally designed to treat influenza but has also attracted attention for its potential activity against other RNA viruses.

UK health minister Sharon Hodgson welcomed the shipment, describing the medicines as an important addition to the country’s outbreak response measures.

She expressed her gratitude to the Japanese authorities for supporting the UK’s preparedness strategy as health officials continue to monitor developments linked to hantavirus infections.

Concerns rise following cruise ship outbreak

The latest concerns emerged after a hantavirus outbreak was linked to a luxury cruise ship earlier this month.

Several passengers reportedly became ill, while three people later died from complications associated with the virus.

Hantavirus infections are commonly transmitted through contact with infected rodents or their droppings, although limited human-to-human transmission has been documented in rare cases.

According to the UK Health Security Agency (UKHSA), nine asymptomatic contacts connected to the outbreak had arrived in the UK as of May 17.

Despite the development, the agency continues to maintain that the overall risk of widespread transmission across the country remains very low.

Even so, health authorities described the acquisition of favipiravir as a critical precautionary measure to strengthen the UK’s readiness should isolated cases emerge domestically.

Favipiravir’s role and regulatory status

Favipiravir received approval in Japan in 2014 for the treatment of influenza and is marketed under the brand name Avigan.

However, Japan primarily reserves the medicine for emergency stockpiling during pandemics rather than routine prescribing.

The antiviral gained global attention during the COVID-19 pandemic because of its mechanism of inhibiting RNA polymerase, which researchers believed could interfere with viral replication.

Nevertheless, several clinical trials later showed limited effectiveness against COVID-19 infections.

At present, no human clinical studies have confirmed favipiravir’s effectiveness against Hantavirus, meaning any potential use in the UK would be off-label.

The medicine has also not received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA).

Growing calls for new antiviral investments

The Hantavirus outbreak has also renewed concerns about the global shortage of targeted antiviral therapies.

Currently, no vaccines or treatments have been specifically approved for Hantavirus infections.

Analysts at GlobalData noted that rising infectious disease outbreaks linked to climate change, expanding global travel, and urbanisation continue to place pressure on healthcare systems worldwide.

Infectious disease analyst Anaelle Tannen warned that the growing burden of emerging viral threats is becoming increasingly concerning as antimicrobial resistance reduces the effectiveness of existing treatments and the pipeline for novel antivirals remains limited.